Keywords: merck, serono, matuzumab, misses, ph, ii, mcrc

Merck Serono's matuzumab misses Ph II mCRC endpoint; future doubts

Article | 03 September 2007

Print This

German Swiss drugmaker Merck Serono, a division of Merck KGaA, says that a Phase II trial investigating the humanized monoclonal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in